Pembrolizumab (PEM) and nivolumab (NIV) are checkpoint inhibitors that inhibit programmed cell death 1 (PD-1), which is a transmembrane protein expressed on immune cells that inhibits T-cell destruction of tumor cells. The gene discussed is PDCD1; the disease is neoplasm.